Multimodal Imaging for Precancerous Oral Conditions
What You Need to Know Before You Apply
What is the purpose of this trial?
This early phase I trial studies how well multimodal imaging works for surveillance in patients with oral potentially malignant disorders. New types of imaging devices may help doctors decide if a lesion in the mouth is pre-cancerous or cancerous.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
Is the multimodal imaging treatment generally safe for humans?
How is the treatment for precancerous oral conditions using multimodal imaging unique?
This treatment is unique because it combines multiple imaging techniques, including fluorescence imaging and high-resolution microendoscopy, to noninvasively evaluate oral lesions. It allows for real-time visualization and analysis, helping to identify suspicious areas and avoid unnecessary biopsies, which is not typically possible with standard methods.678910
What data supports the effectiveness of the treatment Fluorescence Imaging, High-Resolution Microendoscopy, HRME, High-Resolution Microendoscopy, Proflavine Hemisulfate for precancerous oral conditions?
Research shows that high-resolution microendoscopy with proflavine can help visualize and distinguish between normal and abnormal tissue in real-time, which is useful for early detection of oral cancer and its precursors. This imaging technique has been effective in identifying changes in epithelial tissue, which is important for detecting early signs of cancer.13568
Who Is on the Research Team?
Ann M. Gillenwater
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with oral lesions that may become cancerous, a history of resected oral cancer, or exposure to tobacco/alcohol. Participants must be willing and able to consent. Pregnant individuals or those allergic to proflavine/acriflavine cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa, along with brush and incisional biopsies, repeated every 3-4 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Fluorescence Imaging
- High-Resolution Microendoscopy
- Proflavine Hemisulfate
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator